Immunocore Holdings plc provided Preliminary Unaudited revenue guidance for the fourth quarter and full year 2023. The company expects to report preliminary unaudited net product revenue (?net sales?) arising from the sales of KIMMTRAK (tebentafusp) of approximately $66 million for the fourth quarter of 2023

The company expects to report preliminary unaudited new product revenue arising from the sales of KIMMTRAK (tebentafusp) of approximately $235 million for the full year 2023 in accordance with U.S. general accepted accounting principles (U.S. GAAP).